COVID-19

The precisionlife platform can analyse large scale, complex multi-omic and epidemiological data to generate disease insights that are not possible with current tools. We can turn our analyses around within hours even for relatively large populations and routinely work with very large anonymized patient datasets.

Using this platform we have identified 59 re-purposing drug candidates that could be used to develop new therapeutic strategies to increase the survival rate of patients who develop sepsis while suffering from severe COVID-19.

The new study identifies genetic risk factors for sepsis especially in the context of COVID-19, and use these insights to identify existing drugs that might be used to treat life-threatening late-stage disease. 

For more information, click here, or view the study in full. 

We believe that our tools and expertise are particularly helpful in analyzing the COVID-19 patient datasets currently being generated, and would welcome approaches from relevant parties, both in the UK and further afield.

For more information please see below, or contact us at covid-19@precisionlife.com.

Analytics platform now available for COVID-19 coronavirus research community

We are now extending our relationships with some of the largest COVID-19 collaborative research projects and are offering free use of our unique analytics platform and support from its data and biomedical science teams to the on-going collaborative efforts of the medical research community in the fight against COVID-19 coronavirus.

Our precisionlife platform can analyse large scale, complex multi-omic and epidemiological data to generate disease insights that are not possible with current tools. It is routinely used to analyse very large anonymised patient datasets (>100,000 patients) and with detailed insights into complex diseases returned within hours.

The platform can be used to help:

  • Identify the complex genetic factors associated with patients’ different disease severity and outcomes
  • Understanding risk factors such as smoking, gender, ethnicity, blood group and underlying health conditions
  • Developing tests to identify whether people are at high- / low-risk for serious forms of the disease
  • Informing the hunt for existing drugs that will be effective for given patient sub-groups, especially those at risk of late-stage disease
  • Identification of novel drugs targets especially for more serious late-stage disease

To be effective, the tools require data from a minimum of several hundred COVID-19 patients, ideally including genotype/whole genome sequence with additional data including disease severity, co-morbidities, and epidemiological/phenotype information such as blood group, smoking, gender, ethnicity etc. The methods work hypothesis-free and do not require training.

The platform has been validated on over 20 complex disease studies and with disease specialists, development partners and in pre-clinical assays/models. Several of these studies have focused on respiratory and immune response/auto-immune diseases.

For more information see the links below or contact covid-19@precisionlife.com.